Ascendis Pharma

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Ascendis Pharma (NASDAQ: ASND) resulting from allegations that Ascendis may have issued materially misleading business information to the investing public.

If you purchased Ascendis securities and would like to join the prospective action, please click “Join This Class Action.”

If you purchased Ascendis securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of investigation:

On April 3, 2023, before market hours, Ascendis announced that the “U.S. Food & Drug Administration (“FDA”) has notified the Company that, as part of their ongoing review, the FDA has identified deficiencies in the Company’s New Drug Application (“NDA”) for TransCon PTH (palopegteriparatide) in hypoparathyroidism that at this time precludes them from holding further discussions about labeling and post-marketing requirements/commitments. The deficiencies were not disclosed in the letter.”

On this news, the price of Ascendis’ American Depository Shares (“ADSs”) fell as much as 34.71% in intraday trading to open at $67.12 on April 3, 2023.

Follow us on:
Company Name: Ascendis Pharma
Stock Symbol: ASND
Class Period: N/A
Court: N/A

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Scroll to Top